Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments

State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.

Trump_Donald_160716_1200x675

President Trump offered a more glowing assessment of the FDA in his first official State of the Union address, but also touched on two areas that could make industry feel uneasy: drug pricing and "right-to-try" legislation.

After previously slamming FDA as having burdensome regulations at a joint session of Congress last year, Trump praised the agency...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet